CCNE1 and endometrioid tumor: Notably, our latest results validate our initial findings, with 66% of non-endometrioid subtypes harboring CCNE1 amplification compared to 8% of endometrioid tumors, demonstrating a strong association between CCNE1 amplification and non-endometrioid subtypes (p < 0.0001).